The People vs. AbbVie
Today, 9 May 2025, is an important day in court for the Dutch Pharmaceutical Accountability Foundation (PAF). In February 2023, PAF started a court...
The Italian Exception – A personalised approach to accessing high-priced patented medicines
At the end of March 2017, the Italian Minister of Health Beatrice Lorenzin has authorised the importation of generic medicines. She did this with...
Humiragate: AbbVie’s desperate attempts to keep its monopoly
A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...
2018 Round-up of Noteworthy Medicines Law and Policy Events
We are reaching the end of 2018: Time for our end-of-the-year roundup of some significant developments in medicines law and policy.
January
The Chilean parliament started...
UN High-Level Panel on Access to Medicines calls for stronger public leadership in innovation...
The UN High-Level Panel on Access to Medicines published its report on 14 September. The Panel was established on 19 November 2015 by UN...
Imagine if health and trade ministers would meet in one room this week
A earlier version of this commentary was published on 28 November 2021 by Barron's.
This is a time of missed opportunities. This week, trade ministers...
Modifier la législation européenne pour mettre en œuvre la licence d’office en France
Selon le Dr Thierry Philip, Président de l’institut Curie, la hausse des prix des nouveaux traitements contre le cancer « est devenue intenable. »
L’augmentation croissante du prix...
Vaccine knowledge needs to be a global public good: Remarks to the World Trade...
Ellen ‘t Hoen, Medicines Law & Policy, at the World Trade Organization-World Health Organization High-Level Dialogue on Expanding COVID-19 Vaccine Manufacturing to Promote Equitable...
Medicines Law & Policy welcomes WHO’s Solidarity Call to Action to realise equitable global...
The World Health Organization today with Costa Rica launched the "COVID-19 Technology Access Pool (C-TAP)" to ensure that knowledge, data and intellectual property are...
Generic versions of a lifesaving cystic fibrosis treatment will save patients $360,000 a year...
Generic versions of a cystic fibrosis treatment will now be available at $6,375 per child, per year under a new scheme – offering hope...